RK

Ritesh Khetarpal

Active Director Director DIN 10645701
DIN 10645701 First appointment Jun 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value •••• Premium profile

About Ritesh Khetarpal

Data last updated:

Ritesh Khetarpal is a Director at Venor Pharma Limited (since 2024). The company operates in Pharma. Venor Pharma Limited reported revenue of ₹106 Cr (FY 2025).

DIN 10645701
Primary Designation Director
Industry Pharma
First Appointment 01 Jun 2024
Oldest Company Age 13 yrs
Largest company Venor Pharma Limited · ₹106 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Venor Pharma Limited U74900DL2013PLC251565
Director01 Jun 20242013₹106 Cr (FY 2025)Active

Board colleagues of Ritesh Khetarpal

Directorship timeline

Open interactive timeline →
Venor Pharma Limited
Premium access

Shareholding and investment profile for Ritesh Khetarpal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ritesh Khetarpal

Ritesh Khetarpal currently holds 1 directorship: Venor Pharma Limited (Director, since 01 Jun 2024, revenue ₹106 Cr (FY 2025)).

Ritesh Khetarpal was first appointed on 01 Jun 2024 as Director at Venor Pharma Limited.

The current boards of Ritesh Khetarpal's companies include Savita Verma (Venor Pharma Limited), Shivam Verma (Venor Pharma Limited), Shubham Verma (Venor Pharma Limited), Vishwas Verma (Venor Pharma Limited), Yogesh Kapoor (Venor Pharma Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available